The evolution of iron chelators for the treatment of iron overload disease and cancer.
about
Retinal iron homeostasis in health and diseaseThe molecular effect of metastasis suppressors on Src signaling and tumorigenesis: new therapeutic targetsPharmacology of iron transportIron and copper in male reproduction: a double-edged swordHydroxamic acids as potent inhibitors of Fe(II) and Mn(II) E. coli methionine aminopeptidase: biological activities and X-ray structures of oxazole hydroxamate-EcMetAP-Mn complexesIron homeostasis and toxicity in retinal degenerationIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesQuantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugsG2/M Cell Cycle Arrest and Tumor Selective Apoptosis of Acute Leukemia Cells by a Promising Benzophenone Thiosemicarbazone CompoundLipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Synthesis, Physicochemical Studies, Molecular Dynamics Simulations, and Metal-Ion-Dependent Antiproliferative and Antiangiogenic Properties of Cone ICL670-Substituted Calix[4]arenesKinetic and thermodynamic characterization of C-N bond rotation by N-methylacetohydroxamic acid in aqueous media.Structure-antiproliferative activity studies on l-proline- and homoproline-4-N-pyrrolidine-3-thiosemicarbazone hybrids and their nickel(ii), palladium(ii) and copper(ii) complexes.Copper(ii) thiosemicarbazone complexes induce marked ROS accumulation and promote nrf2-mediated antioxidant response in highly resistant breast cancer cells.Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells.Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone.The Eltrombopag antitumor effect on hepatocellular carcinoma.Proteomic study on gender differences in aging kidney of mice.Antiproliferative effect on HepaRG cell cultures of new calix[4]arenes. Part II.Iron chelators in photodynamic therapy revisited: synergistic effect by novel highly active thiosemicarbazones.CrMAPK3 regulates the expression of iron-deficiency-responsive genes in Chlamydomonas reinhardtiiMinding metals: tailoring multifunctional chelating agents for neurodegenerative disease.Effect of the piperazine unit and metal-binding site position on the solubility and anti-proliferative activity of ruthenium(II)- and osmium(II)- arene complexes of isomeric indolo[3,2-c]quinoline-piperazine hybrids.Advances in iron chelation: an update.Vibriobactin antibodies: a vaccine strategy.The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway.Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.The anticancer agent di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes prosurvival autophagy by two mechanisms: persistent induction of autophagosome synthesis and impairment of lysosomal integrity.The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark--from iron metabolism to tumorigenesis.Desferrithiocin: a search for clinically effective iron chelators.Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1.A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics.A novel antimycobacterial compound acts as an intracellular iron chelator.Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships.Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties.Novel immunosuppressive agent caerulomycin A exerts its effect by depleting cellular iron contentIn-Depth Analyses of B Cell Signaling Through Tandem Mass Spectrometry of Phosphopeptides Enriched by PolyMAC.Nitric oxide storage and transport in cells are mediated by glutathione S-transferase P1-1 and multidrug resistance protein 1 via dinitrosyl iron complexes.Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy.Pro-Oxidant Activity of Amine-Pyridine-Based Iron Complexes Efficiently Kills Cancer and Cancer Stem-Like Cells
P2860
Q21131069-9C5AA91E-658A-46FA-A3FE-CD20C114E274Q26782593-3B4988E9-B4BF-47B7-A2A9-0B0154827C9CQ27009387-116AAEC3-B3B8-4931-A803-B8192616A343Q27027411-2859436A-C061-4B88-95B6-EECDF427814FQ27678407-D87B4DFC-60AC-4E37-9970-0D2F222B7647Q28252419-F9AEF7FE-78B7-43A4-BBC1-F19608E79D68Q28388335-1A281B5F-D5EA-4531-8482-BDDE868D5AFAQ28539989-39CA0EC0-1820-4AB2-B92A-7CE94FC48278Q28547905-10A6D9EA-6A78-4DB5-B24F-B256379C3723Q30366990-88D468D5-1679-4F53-88C6-86384F0B7922Q30615373-F5F5590C-B4CF-4E70-9C6F-BEA131E9F3B3Q31007535-479F0292-26DB-4699-8F23-51A743F6AE9CQ31119195-FD11A163-45D2-42A1-806B-3DD46F8D82F9Q31172464-27C97CD1-B5FD-4A5E-BFBB-484AF02B2416Q33324778-7CCD0A8E-F300-492A-B310-F1D781D6310DQ33341069-70316BDB-4987-4345-810C-10625664EB11Q33426135-5FE566C8-0D6D-46E9-B60E-D03F4232B067Q33428748-5EB95DD9-5C56-4924-92B0-C60E70BB0830Q33603341-A72FA6AF-C391-4C77-A429-C5C65278BA82Q33636546-BA17772A-98C8-4D3D-8A79-C469627658A6Q33697254-F567DDF0-9F31-4031-9C29-94BDD8CAA795Q33813567-66258990-C40F-480A-AB2A-9086A23EBE6DQ33864513-6204FCA7-3FAF-4E3B-A5D2-DAFC362DC76EQ34174307-63167B8D-1D24-42FF-9336-06710667B8E7Q34181069-1ECE3410-60A8-4024-94A2-7C41BE45D1E8Q34483637-38BEA4C7-7670-4509-BDF8-ED6780AA3F8EQ34568034-7F893704-F061-49CD-A68C-8EA02D018454Q34580395-6385EB5B-6351-4BAE-8B23-E8EE50AF9748Q34621913-6C8B2828-83C8-4215-8DEF-19A156FF6B88Q34631577-7DBF0F5C-A116-45B1-AF80-6725DBD1B72CQ34869589-61F86BC2-9CF2-4C22-945E-9F9D85F5D2A8Q35075541-5DBE27AF-DEF1-45B1-B78A-A79E680C1F6FQ35168885-2708AA73-55E1-4A0A-8B32-D55B0CB09352Q35348485-C299640B-AB72-477F-A823-F9B2FCD01815Q35418008-E0B3D4AD-0DCB-4E95-A3BC-8DB0A7BE01CDQ35484363-A6F6C56E-9CD6-45F1-A54B-D844D7577D82Q35563986-3C2C70F5-9141-401D-839F-6F8B994F628BQ35643805-DF2EB6C2-EFAA-4B0E-8F74-EECA6FB2B627Q35657936-DC6E3811-C5E0-4B1E-BF05-8C61D0F35C59Q35773665-26CC7FBC-E852-41A4-85B1-D603738AE50E
P2860
The evolution of iron chelators for the treatment of iron overload disease and cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The evolution of iron chelators for the treatment of iron overload disease and cancer.
@ast
The evolution of iron chelators for the treatment of iron overload disease and cancer.
@en
type
label
The evolution of iron chelators for the treatment of iron overload disease and cancer.
@ast
The evolution of iron chelators for the treatment of iron overload disease and cancer.
@en
prefLabel
The evolution of iron chelators for the treatment of iron overload disease and cancer.
@ast
The evolution of iron chelators for the treatment of iron overload disease and cancer.
@en
P356
P1476
The evolution of iron chelators for the treatment of iron overload disease and cancer
@en
P2093
Danuta S Kalinowski
Des R Richardson
P304
P356
10.1124/PR.57.4.2
P577
2005-12-01T00:00:00Z